Table 2.

AZD1446 differences to placebo on efficacy measures at week 2 (clinical symptoms, intent-to-treat population)

Score	Treatment	Nicotine non-users					Treatment	Nicotine users
		Number	LS mean	Difference to placebo				Number	LS mean	Difference to placebo
				LS mean	95 %CI	P value				LS mean	95 %CI	P value
CAARS-INVa, DSM-IV total score	Placebo	40	29.0				Placebo	17	29.4
	80 mg tid	26	29.1	0.09	−3.26, 3.44	0.80	80 mg tid	18	32.7	3.37	−2.36, 9.11	0.97
	80 mg qd	26	27.8	−1.28	−4.65, 2.10	0.39	80 mg qd	20	31.6	2.19	−3.49, 7.87	0.91
	10 mg tid	26	28.5	−0.51	−3.89, 2.87	0.64
DSM-IV inattention score	Placebo	40	16.7				Placebo	17	15.6
	80 mg tid	26	17.0	0.25	−1.95, 2.45	0.99	80 mg tid	18	18.3	2.70	−0.66, 6.05	0.13
	80 mg qd	26	16.4	−0.36	−2.57, 1.84	0.97	80 mg qd	20	17.4	1.80	−1.51, 5.11	0.37
	10 mg tid	26	16.6	−0.19	−2.39, 2.01	0.99
DSM-IV hyperactivity–impulsivity score	Placebo	40	12.4				Placebo	17	13.9
	80 mg tid	26	12.5	0.13	−1.67, 1.94	1.00	80 mg tid	18	14.8	0.84	−2.09, 3.76	0.75
	80 mg qd	26	11.5	−0.87	−2.69, 0.95	0.55	80m qd	20	14.5	0.64	−2.27, 3.54	0.84
	10 mg tid	26	12.4	−0.04	−1.86, 1.78	1.00
ADHD Index	Placebo	40	16.2				Placebo	17	17.4
	80 mg tid	26	16.2	−0.02	−2.14, 2.10	1.00	80 mg tid	18	19.9	2.51	−0.77, 5.80	0.16
	80 mg qd	26	16.2	−0.02	−2.16, 2.11	1.00	80 mg qd	20	19.9	2.54	−0.72, 5.80	0.15
	10 mg tid	26	16.7	0.54	−1.59, 2.67	0.89
Clinical Global Impression (CGI) Severity of illness score	Placebo	40	4.1				Placebo	17	4.1
	80 mg tid	26	4.2	0.13	−0.21, 0.49	0.68	80 mg tid	18	4.2	0.06	−0.44, 0.56	0.95
	80 mg qd	26	4.1	0.05	−0.30, 0.39	0.98	80 mg qd	20	4.4	0.29	−0.21, 0.78	0.32
	10 mg tid	26	4.2	0.11	−0.24, 0.46	0.82

Note that one-sided test of superiority was used for the primary endpoint CAARS-INV, DSM-IV Total score

CI confidence interval, qd once daily, tid three times daily, LS least squares

^aInvestigator-rated